NYSEAMERICAN:OSTX OS Therapies Q3 2025 Earnings Report $1.90 -0.34 (-15.18%) Closing price 04:10 PM EasternExtended Trading$1.90 +0.00 (+0.05%) As of 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast OS Therapies EPS ResultsActual EPS-$0.21Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AOS Therapies Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AOS Therapies Announcement DetailsQuarterQ3 2025Date11/14/2025TimeBefore Market OpensConference Call DateFriday, November 14, 2025Conference Call Time4:00PM ETConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsEarnings Release(8-K)Quarterly Report(10-Q) OS Therapies Earnings HeadlinesOS Therapies: OS Therapies Achieves Statistically Significant 2.5-Year Overall Survival in Phase 2b Trial of OST-HER2 in Fully Resected Pulmonary Metastatic OsteosarcomaJune 2, 2026 | finanznachrichten.deOS Therapies Announces Pricing of its Initial Public Offering on NYSE American - Company to Trade under Symbol “OSTX”May 28, 2026 | businesswire.comSolar is dead. Here’s what replaces it.Starting July 4th, every new solar and wind project in America loses its federal tax credits. But one zero-carbon energy source retains full government backing for eight more years - and it runs around the clock without batteries. Investment in this sector has surged 100x in seven years. The Pentagon named it a top energy priority, California mandated it, and Google, Meta, and Berkshire Hathaway are already under contract. One company controls the entire chain from the ground to the grid.June 30 at 1:00 AM | Behind the Markets (Ad)OS Therapies Delays Quarterly SEC FilingMay 15, 2026 | tipranks.comOS Therapies: OS Therapies Appoints Industry Leader Dr. Craig Eagle as Chief Medical AdvisorMay 15, 2026 | finanznachrichten.deOS Therapies (OSTX) price target increased by 16.67% to 14.28May 15, 2026 | msn.comSee More OS Therapies Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like OS Therapies? Sign up for Earnings360's daily newsletter to receive timely earnings updates on OS Therapies and other key companies, straight to your email. Email Address About OS TherapiesOS Therapies (NYSEAMERICAN:OSTX), a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.View OS Therapies ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Why Wall Street Still Sees Massive Upside for AeroVironment StockManchester United’s Stock Rally Faces a Test Beyond Old TraffordBest Buy’s Turnaround Is Gaining Traction, But Wall Street Still Needs ProofPalantir’s Rough 2026 Start Raises a Bigger Question About Its AI MoatWinnebago Misses Estimates, But Surges 14% After EarningsBlackBerry’s Rally Is Running on a Bigger AI Story Than Earnings AloneTrip.com’s Selloff Raises a Bigger Question About Its Travel Recovery Story Upcoming Earnings PepsiCo (7/9/2026)Delta Air Lines (7/9/2026)Bank of America (7/14/2026)The Goldman Sachs Group (7/14/2026)JPMorgan Chase & Co. (7/14/2026)Wells Fargo & Company (7/14/2026)Citigroup (7/14/2026)Fastenal (7/14/2026)ASML (7/15/2026)Kinder Morgan (7/15/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
